Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research

[video src="https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/serveFlavor/entryId/1_hbnlstt0/flavorId/1_uquopy1e/prn_folder/MNR/prn_id/MVP/prn_flavor/MP4_Codec-H264/prn_filename/8964851_general_marketing_video_14sep2021_1007_MNR.mp4" poster="https://www.germanynewstoday.com/wp-content/uploads/2021/10/lovelace-biomedical-presents-a-new-webinar-on-rare-diseases-and-gene-therapy-preclinical-research.jpg"] ALBUQUERQUE, N.M., Oct. 21, 2021 /PRNewswire/ — Lovelace Biomedical, a contract research organization, who has a vast and storied,…

ALBUQUERQUE, N.M., Oct. 21, 2021 /PRNewswire/ — Lovelace Biomedical, a contract research organization, who has a vast and storied, 70 plus year history and expertise in studying respiratory diseases and developing therapeutics at the preclinical stage, will present a webinar in gene therapies for diseases, and will use Cystic Fibrosis results as a case study.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8964851-lovelace-biomedical-webinar-rare-diseases-gene-therapy-preclinical-research/

Nonclinical development to advance promising Gene Therapies often require the use of novel animal models to prove efficacy and/or safety. This webinar will frame the basis of typical nonclinical study needs to advance gene therapies from concept to clinic; with consideration of regulatory guidance and science in the design of experiments that may be considered by the FDA. The presentation will frame the overall regulatory and scientific constructs that are ‘typical’, and use cystic fibrosis as a hallmark example of the use of various animal model approaches to evaluate safety and efficacy for therapeutics, including a discussion of drug delivery and non-pulmonary safety evaluation.

Register for the webinar here: https://www.webcaster4.com/Webcast/Page/2117/43201

Speakers

Dr. Jake McDonald is a Senior Scientist and Vice President of Applied Science at Lovelace Biomedical. In this role he serves as Director and Technical Advisor to collaborators in the design and execution of nonclinical development packages related to toxicology and pharmacology. Much of his emphasis is in the development of Gene Therapy technologies under GLP to support IND submissions. Dr. McDonald will present on the framework for the use of rare disease models and regulatory considerations for safety.

Dr. John Engelhardt is Professor and Chair of the Department of Anatomy and Cell Biology and Director of the Center for Gene Therapy at the University of Iowa Roy J. and Lucille A. Carver College of Medicine. His research focuses on the following areas: 1) the study of the molecular and cellular pathogenesis of cystic fibrosis (CF) related diabetes and lung disease, 2) the study of airway and pancreatic stem cells, 3) the development of animal models of CF lung and pancreatic diseases, and 5) the development of gene therapies for CF with a focus on recombinant parvoviruses and their transduction biology.

About Lovelace Biomedical

Lovelace Biomedical is a contract research organization that conducts research to advance pharmaceutical and biotechnology companies in their complex drug development studies from the preclinical stage, and on to clinical trials. For over 70 years, the organization has leveraged its multidisciplinary expertise in toxicology, gene therapy, neurological disorders, infectious disease, and medical countermeasures.

Follow Lovelace Biomedical

Linkedin 

Twitter

 

15+ years of Gene Therapy Preclinical Research

 

Jake McDonald, PhD

 

John Engelhardt, PhD

 

Lovelace_Logo

 

Cision View original content:https://www.prnewswire.com/news-releases/lovelace-biomedical-presents-a-new-webinar-on-rare-diseases-and-gene-therapy-preclinical-research-301406082.html

SOURCE Lovelace Biomedical